Table 1.
Baseline Characteristics of Subjects in the Cohort and Analysis (Completers or Late)
| PRISm | GOLD 0 | GOLD 1 | GOLD 2 | GOLD 3 | GOLD 4 | |
|---|---|---|---|---|---|---|
| Sample size | 318 | 1,223 | 250 | 580 | 357 | 133 |
| Completers | 225 | 878 | 185 | 412 | 229 | 71 |
| Late | 93 | 345 | 65 | 168 | 128 | 62 |
| Age, yr, mean (SD) | 58.2 (8.1) | 57.6 (8.8) | 63.7 (8.8) | 63.1 (8.6) | 64.3 (8.1) | 63.3 (7.5) |
| Female, n (%) | 171 (54) | 640 (52) | 109 (44) | 279 (48) | 171 (48) | 58 (44) |
| Race, n (%) | ||||||
| Non-Hispanic white | 173 (54) | 775 (63) | 203 (81) | 440 (76) | 286 (80) | 110 (83) |
| Smoking, n (%) | ||||||
| Current | 107 (34) | 382 (31) | 65 (26) | 124 (21) | 34 (10) | 5 (4) |
| Former | 126 (40) | 517 (42) | 128 (51) | 319 (55) | 226 (63) | 98 (74) |
| Intermittent | 85 (27) | 324 (26) | 57 (23) | 137 (24) | 97 (27) | 30 (23) |
| BMI, mean (SD) | 32.0 (6.9) | 28.8 (5.8) | 27.2 (5.2) | 28.8 (6.0) | 28.1 (6.2) | 26.7 (5.7) |
| FEV1 at baseline visit, mean (SD) | ||||||
| Liters | 2.05 (0.49) | 2.84 (0.68) | 2.62 (0.65) | 1.86 (0.50) | 1.13 (0.29) | 0.68 (0.18) |
| % predicted | 70.6 (8.0) | 97.7 (11.3) | 91.4 (9.1) | 64.7 (8.5) | 40.4 (5.6) | 23.4 (4.3) |
| COPD medications, n (%) | ||||||
| ICS only | 26 (8) | 18 (1) | 10 (4) | 41 (7) | 45 (13) | 28 (22) |
| LAMA | 26 (8) | 28 (2) | 23 (9) | 158 (28) | 184 (52) | 88 (67) |
| ICS and LABA | 44 (14) | 42 (3) | 23 (9) | 169 (30) | 192 (54) | 83 (63) |
| LABA only | 5 (2) | 5 (0.4) | 2 (1) | 34 (6) | 29 (8) | 23 (18) |
| Emphysema, mean (SD) | 1.9 (2.9) | 2.6 (3.0) | 7.2 (6.8) | 8.7 (8.2) | 18.2 (12.9) | 25.3 (12.8) |
| BDR, L, mean (SD) | 0.13 (0.34) | 0.09 (0.28) | 0.25 (0.44) | 0.36 (0.48) | 0.38 (0.49) | 0.28 (0.45) |
Definition of abbreviations: BDR = bronchodilator responsiveness; BMI = body mass index; COPD = chronic obstructive pulmonary disease; GOLD = Global Initiative for Chronic Obstructive Lung Disease; ICS = inhaled corticosteroids; LABA = long-acting β-agonists; LAMA = long-acting antimuscarinic; PRISm = preserved ratio impaired spirometry.
Sample sizes available for analysis for PRISm, GOLD 0, GOLD 1, GOLD 2, GOLD 3, and GOLD 4 were as follows: 312, 1,209, 248, 560, 352, and 127 for ICS only; 312, 1,213, 249, 566, 355, and 132 for ICS and LABA; 312, 1,211, 248, 566, 354, and 131 for LAMA; 309, 1,209, 248, 562, 352, and 128 for LABA; 299, 1,156, 240, 550, 333, and 119 for emphysema; and 314, 1,205, 248, 576, 355, and 132 for BDR, respectively. For all other variables, sample sizes are as given in the first row.